Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Cosmet Dermatol ; 23(1): 44-61, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37605478

ABSTRACT

BACKGROUND: Rosacea is a chronic inflammatory disease usually associated with persistent erythema and periodic flushing. This disease is difficult to treat, and the outcomes are often unsatisfactory and prone to recurrence. In recent years, botulinum toxin has been used as a new treatment for rosacea; however, its efficacy and safety remain under discussion. Although a systematic review of the effectiveness and safety of botulinum toxin has been previously conducted by other researchers, our systematic review and meta-analysis evaluate the efficacy of botulinum toxin from a more comprehensive and detailed perspective to provide evidence for clinicians. METHODS: Any study using botulinum toxin for the treatment of rosacea was considered for the analysis. RESULTS: A total of 22 studies were included, 9 of which were randomized controlled trials involving 720 subjects. After treatment, all studies showed varying degrees of improvement in patient signs and symptoms along with reduced Clinician's Erythema Assessment (CEA) scores. The improvement was maintained for several months, and the adverse effects were mild and self-limiting. CONCLUSION: Botulinum toxin may be an effective treatment for patients with rosacea; however, further clinical evidence is needed to confirm its long-term efficacy and side effects. The study was preregistered with Prospero (CRD42022358911).


Subject(s)
Botulinum Toxins, Type A , Botulism , Rosacea , Humans , Botulinum Toxins, Type A/adverse effects , Botulism/chemically induced , Botulism/complications , Botulism/drug therapy , Systematic Reviews as Topic , Meta-Analysis as Topic , Rosacea/drug therapy , Rosacea/complications , Erythema/diagnosis , Erythema/drug therapy , Erythema/etiology , Treatment Outcome , Randomized Controlled Trials as Topic
2.
Clin Cosmet Investig Dermatol ; 15: 2841-2844, 2022.
Article in English | MEDLINE | ID: mdl-36582849

ABSTRACT

A 78-year-old female patient with right ear agenesis presented with a skin manifestation of approximately 7 cm × 8 cm deep-invasive ulcer with well-defined borders and a small amount of yellow purulent discharge visible at the base, surrounded by pearl-like margins in a dyke-like elevation, covered with a small amount of necrotic tissue and black crust. The disease lasted for more than 20 years and was diagnosed as giant basal cell carcinoma complicated by primary cutaneous aspergillosis after two histopathological examinations of the skin lesions. There are similarities in the clinical manifestations of these two diseases, which need to be differentiated, and the simultaneous complications are infrequent. It has not been reported.

3.
J Healthc Eng ; 2021: 8493572, 2021.
Article in English | MEDLINE | ID: mdl-34422248

ABSTRACT

Although the evidence based on current human, animal, or molecular biology can explain some of the relationships between CDK4 and cancer, there is no pan-cancer analysis of the gene CDK4 in human skin tumors. Therefore, the potential carcinogenic effects of CDK4 in 33 tumors were initially explored in the datasets of the GEO (Gene Expression Omnibus) and the CGA (Cancer Genome Atlas). We found that CDK4 was highly expressed in most cancers and that CDK4 performance levels significantly correlated with the prognosis of cancer patients. These were found in our preliminary exploration. In addition, we used the dataset in tumors such as cutaneous melanoma or lung adenocarcinoma and found increased levels of phosphorylation of r24 l/C/h/s. In addition, fibroblast infiltration associated with CDK4 cancer was observed in head and neck, sarcoma, and melanoma skin. Using this pan-cancer study, our group has provided a comprehensive preliminary demonstration of the oncogenic effects of the CDK4 gene on different human skin tumors.


Subject(s)
Cyclin-Dependent Kinase 4 , Head and Neck Neoplasms , Melanoma , Oncogenes , Skin Neoplasms , Animals , Cyclin-Dependent Kinase 4/genetics , Head and Neck Neoplasms/genetics , Humans , Melanoma/genetics , Prognosis , Sarcoma/genetics , Skin Neoplasms/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...